Skip to main content

Table 2 aPS/PT IgG/IgM, aPL IgG/IgM, and ATI IgG during the anti-TNFa treatment of 30 IBD patients with infliximab

From: Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases

 

W2 n (%)

W14 n (%)

aPS/PT IgG

9 (30 %)

3 (10 %)

aPS/PT IgM

0

0

aPS/PT IgG and IgM

3 (10 %)

2 (6.7 %)

aPL IgG

1 (3.3 %)

1 (3.3 %)

aPL IgM

4 (13.3 %)

4 (13.3 %)

aPL IgG and IgM

0

0

ATI IgG

2 (6.7 %)

6 (20 %)

  1. aPS/PT phosphatidylserine-dependent anti-prothrombin antibodies, aPL antiphospholipid antibodies, ATI antibodies to infliximab, W2 second week of the biological treatment, W14 14th week of the biological treatment
Back to article page

Autoimmunity Highlights

ISSN: 2038-3274

Contact us